Physician profile
Eric P Kleinbaum
NPI 1932140159
$5,556.48
in general payments reported to CMS, 2019-2025
58 companies · $1,865 in 2025
The $1,865 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $335 · 2021: $509 · 2022: $760 · 2023: $952 · 2024: $349 · 2025: $1,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.68 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $525.16 | 2019-2025 | |
| Eisai INC. | $365.79 | 2019-2025 | |
| Astellas Pharma US INC | $360.81 | 2019-2025 | Xtandi, Xospata |
| Novartis Pharmaceuticals Corporation | $338.51 | 2019-2025 | |
| Amgen INC. | $302.98 | 2019-2023 | Kyprolis |
| Janssen Biotech, INC. | $289.99 | 2019-2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $241.78 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $227.07 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Fennec Pharmaceuticals, INC. | $198.29 | 2025 | Fyarro |
| Tempus Ai, INC | $190.98 | 2025 | Xt Cdx |
| Puma Biotechnology, INC. | $184.78 | 2020-2022 | |
| Genzyme Corporation | $159.15 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $130.00 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Gilead Sciences, INC. | $128.98 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kleinbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.